NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 135 filers reported holding NEKTAR THERAPEUTICS in Q4 2013. The put-call ratio across all filers is 0.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2016 | $449,000 | -71.3% | 36,604 | -59.8% | 0.00% | -72.7% |
Q3 2016 | $1,562,000 | +7.9% | 90,961 | -10.5% | 0.01% | 0.0% |
Q2 2016 | $1,447,000 | +143.2% | 101,685 | +135.1% | 0.01% | +120.0% |
Q1 2016 | $595,000 | -54.4% | 43,245 | -44.1% | 0.01% | +25.0% |
Q4 2015 | $1,304,000 | -57.4% | 77,400 | -72.3% | 0.00% | -76.5% |
Q3 2015 | $3,060,000 | +0.8% | 279,197 | +15.0% | 0.02% | -5.6% |
Q2 2015 | $3,036,000 | +76.7% | 242,715 | +55.4% | 0.02% | +38.5% |
Q1 2015 | $1,718,000 | +283.5% | 156,200 | +264.1% | 0.01% | +1200.0% |
Q3 2013 | $448,000 | – | 42,900 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
CM Management, LLC | 50,000 | $858,000 | 0.62% |
Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |